Remus Pharmaceuticals
Remus Pharmaceuticals (REMUS) share price was ₹874.35 at the 28 Oct 2026 close; market capitalisation ₹1,030 Cr; sector Healthcare. The share price rose 33.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue rose 30.2% year on year to ₹453 Cr and net profit was ₹25 Cr, against ₹21 Cr a year earlier (compared with Mar 2025). Promoters held 70.95% of Remus Pharmaceuticals in Sep 2026, unchanged from Mar 2026. Its Tapetide Score is 57/100 (Good) as of 28 Oct 2026.
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 29 Oct 2026, 10:07 IST · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,765.90 | 35.03 | 4,23,699 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,653.50 | 87.62 | 2,56,270 Cr | 15.29 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,595.20 | 72.14 | 1,74,787 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,190.10 | 108.21 | 1,18,334 Cr | 22.33 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.60 | 26.29 | 1,17,865 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,337.30 | 34.64 | 1,11,622 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,363.10 | 32.66 | 1,10,119 Cr | 3.11 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Remus Pharmaceuticals (this company) | ₹875.00 | — | 1,031 Cr | 2.94 | 0.11% | 11.91% | 14.11% | — | — |
| Median 8 companies | ₹1,564.50 | 35.03 | 1,18,099 Cr | 4.71 | 0.47% | 12.98% | 16.41% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 81/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is almost debt free.
- Debtor days have improved from 107 to 59.8 days.
- Company's working capital requirements have reduced from 67.1 days to 49.2 days
Weaknesses
1- Company has a low return on equity of 12.9% over last 3 years.
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 7% · Mar 2026
Quarterly Results
| Particulars | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 29 | 185 | 273 | 348 | 400 | 453 |
| Expenses | 20 | 165 | 252 | 323 | 373 | 424 |
| Operating Profit | 9 | 20 | 20 | 25 | 27 | 30 |
| OPM % | 32% | 11% | 8% | 7% | 7% | 7% |
| Other Income | 2 | 3 | 3 | 3 | 3 | 4 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 |
| PBT | 10 | 22 | 22 | 25 | 28 | 31 |
| Tax % | 25% | 15% | 16% | 19% | 23% | 21% |
| Net Profit | 6 | 19 | 19 | 21 | 22 | 25 |
| EPS (₹) | 4.87 | 13.16 | 11.87 | 13.57 | 14.85 | 16.54 |
Profit & Loss
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 213 | 620 | 854 |
| Expenses | 184 | 575 | 797 |
| Operating Profit | 29 | 46 | 57 |
| OPM % | 14% | 7% | 7% |
| Other Income | 3 | 5 | 7 |
| Interest | 0 | 1 | 1 |
| Depreciation | 1 | 2 | 3 |
| PBT | 30 | 47 | 59 |
| Tax % | 20% | 19% | 22% |
| Net Profit | 24 | 38 | 46 |
| EPS (₹) | 17.69 | 24.64 | 31.39 |
| Div. Payout % | 4% | 3% | 2% |
Balance Sheet
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 1 | 6 | 12 |
| Reserves | 156 | 250 | 339 |
| Borrowings | 14 | 23 | 27 |
| Other Liabilities | 161 | 154 | 201 |
| Total Liabilities | 333 | 433 | 579 |
| Fixed Assets | 14 | 16 | 18 |
| CWIP | 0 | 0 | 8 |
| Investments | 105 | 186 | 275 |
| Other Assets | 215 | 231 | 277 |
| Total Assets | 333 | 433 | 579 |
Cash Flow
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | 4 | 7 | 18 |
| Investing | -9 | -11 | -15 |
| Financing | 24 | 6 | 1 |
| Net Cash Flow | 19 | 2 | 5 |
| Free Cash Flow | 3 | 3 | 4 |
| CFO/EBITDA | 35 | 32 | 49 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 198 | 64 | 60 |
| Inventory Days | 96 | 35 | 35 |
| Days Payable | 209 | 49 | 37 |
| Cash Conversion Cycle | 85 | 50 | 58 |
| Working Capital Days | 98 | 54 | 49 |
| ROCE % | — | 20% | 17% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Remus Pharmaceuticals insights
63 extracted metrics + investor summaries across FY20–FY26.
Documents
Frequently Asked Questions about Remus Pharmaceuticals
What does Remus Pharmaceuticals Ltd do?
Where is Remus Pharmaceuticals Ltd (REMUS) listed?
Which sector does Remus Pharmaceuticals Ltd belong to?
What is the market capitalisation of Remus Pharmaceuticals Ltd?
What is the 52-week high and low of Remus Pharmaceuticals Ltd?
Does Remus Pharmaceuticals Ltd pay dividends?
What is the Return on Equity (ROE) of Remus Pharmaceuticals Ltd?
Company Information
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/REMUS.md for Remus Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.